NAD+ IV Therapy: Evidence, the 2025 Class I Recall, and What the FDA Actually Said

Is NAD+ IV therapy safe and worth it at a med spa or IV bar, given the recent FDA recall news?

NAD+ IV therapy is not FDA-approved for anti-aging, cellular restoration, or cognitive enhancement. While nicotinamide adenine dinucleotide is a natural coenzyme essential for cellular energy production, the injectable preparations sold by IV bars and wellness clinics are compounded substances rather than FDA-approved drugs. In 2025, the FDA took major enforcement actions, classifying a voluntary recall of GenoGenix NAD+ injection lots as Class I—the most serious recall category, reserved for situations where exposure to the product carries a reasonable probability of serious adverse health consequences or death. This recall followed inspections showing high endotoxin contamination levels and sterility assurance failures, which resulted in emergency room hospitalizations for multiple patients experiencing severe shaking, rigors, and acute hypotension. Human clinical trial evidence for the systemic benefits of IV NAD+ remains extremely limited and small in cohort size, with clinical literature indicating that intravenous administration is often poorly tolerated compared to oral precursors like nicotinamide riboside (NR). Patients and providers must prioritize safety and supply chain transparency when evaluating compounded injectables.

---

The Anti-Aging Hype vs. Biological Realities of NAD+

Nicotinamide Adenine Dinucleotide (NAD+) is a vital coenzyme present in every living cell, functioning as a primary driver of mitochondrial energy production, cellular respiration, and ATP generation. It exists in two states: NAD+ (the oxidized form) and NADH (the reduced form). The ratio of these two forms is critical for maintaining cellular redox homeostasis.

As organisms age, systemic levels of NAD+ decline. This decline is associated with mitochondrial decay, reduced energy production, and the onset of age-related metabolic dysfunctions. In the context of longevity medicine, increasing NAD+ levels has become a major therapeutic focus. Preclinical animal models have demonstrated that restoring NAD+ can improve insulin sensitivity, reverse mitochondrial decay, extend lifespan, and support DNA repair mechanisms by activating sirtuins (a family of NAD+-dependent deacetylases) and poly(ADP-ribose) polymerases (PARPs).

These compelling animal studies have fueled a massive commercial wellness trend, prompting med spas, IV bars, and anti-aging clinics to market intravenous NAD+ infusions as a direct mechanism to "reverse cellular aging," "boost cognitive clarity," "detoxify the brain," and "combat fatigue." NAD+ sits in the same unregulated "regenerative" bucket as exosome and stem-cell injections — and as our primer on the FDA regulatory status of exosomes explains, "natural" and "cellular" do not mean reviewed or approved. Translating basic molecular biology and rodent studies into safe, effective clinical therapies for humans requires rigorous human clinical trials, and commercial claims often outpace the peer-reviewed clinical evidence.

Intravenous Infusion vs. Oral Precursors

A key clinical question is whether intravenous administration is the most efficient or safest method for increasing intracellular NAD+ levels. In the human digestive tract, oral NAD+ is rapidly broken down into its constituent precursors, such as nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). Because intact NAD+ molecules do not efficiently cross cell membranes on their own, oral supplementation has focused on smaller precursor molecules like NR and NMN, which enter cells and are rebuilt into NAD+ intracellularly.

Intravenous infusion bypasses the digestive tract, delivering NAD+ directly into the bloodstream. Proponents of IV therapy argue that this bypass achieves superior systemic bioavailability. However, pharmacokinetics studies show that exogenous NAD+ in the plasma is rapidly degraded or sequestered. A pilot clinical trial published in the peer-reviewed literature found that intravenous NAD+ is quickly broken down into its precursors in the extracellular space before being rebuilt inside the cells. This rapid degradation raises questions about the efficiency of IV administration compared to oral precursor supplementation.

Furthermore, direct intravenous delivery of NAD+ can trigger significant physiological stress, primarily due to the activation of purinergic receptors and the accumulation of degradation products like adenosine. Human trials show that patients receiving NAD+ IV infusions frequently report moderate to severe symptoms during the infusion, including:

• Severe chest pressure and tightness
• Acute gastrointestinal distress (nausea, cramping, vomiting)
• Somatic anxiety and hyperventilation
• Increased heart rate and mild transient hypertension
• Muscle soreness and localized cramping

To manage these tolerability issues, clinics must administer NAD+ infusions very slowly, often requiring three to four hours for a single dose of 500 mg. In contrast, oral NR or NMN supplementation is well-tolerated at daily doses up to 1,000 mg twice daily without triggering these acute cardiovascular or gastrointestinal symptoms.

---

Why did the FDA classify the GenoGenix NAD+ recall as Class I in 2025?

To understand the 2025 recalls, it is necessary to examine the regulatory status of compounded medications. Compounded drugs are not FDA-approved. They do not undergo premarket review for safety, efficacy, or quality standards. Because they are not manufactured under standardized, high-volume conditions, they are highly dependent on the quality control, sanitary environment, and sourcing practices of the specific pharmacy preparing them.

The U.S. Food and Drug Administration regulates human drug compounding under two primary sections of the Federal Food, Drug, and Cosmetic (FD&C) Act:

• Section 503A (Traditional Compounding Pharmacies): These pharmacies compound medications based on patient-specific prescriptions. They are regulated primarily by state boards of pharmacy and are subject to traditional compounding standards. They cannot produce drugs in bulk for office use without individual patient prescriptions.
• Section 503B (Outsourcing Facilities): Established under the Drug Quality and Security Act (DQSA), 503B outsourcing facilities are permitted to compound large batches of sterile drugs without patient-specific prescriptions and sell them directly to medical offices and clinics for "office use." 503B facilities are subject to Current Good Manufacturing Practice (CGMP) regulations, which are far stricter than the standards applied to traditional 503A pharmacies. They are also subject to regular FDA inspections.

Under the FD&C Act, compounding regulation is divided as follows:

• Section 503A: Traditional Pharmacies
  • Requires patient-specific prescriptions.
  • Regulated primarily by State Boards of Pharmacy.
  • Subject to USP compounding standards.
• Section 503B: Outsourcing Facilities
  • Allowed to compound bulk drug substances for office use.
  • Regulated directly by the FDA.
  • Subject to strict CGMP regulations.
  • Must use bulk substances that appear on the FDA's approved list or are in shortage.

Chronology of the GenoGenix, LLC FDA Enforcement Actions

In 2025, the FDA took significant regulatory action against GenoGenix, LLC, an outsourcing facility based in Boca Raton, Florida, that supplied sterile injectables—including NAD+ and other "wellness" compounds—to clinics and IV bars nationwide.

1. The Voluntary Recall (July 30, 2025)

On July 30, 2025, GenoGenix initiated a voluntary recall of several lots of sterile drug products. The initial recall was prompted by internal and external inspections that revealed failures in maintaining sterile compounding conditions. The facility could not assure the sterility of its injectables, raising the risk of microbial and chemical contamination.

2. The Class I Recall Classification (October 21, 2025)

Following a detailed review of the contamination profiles, the FDA formally classified the recall of specific GenoGenix NAD+ injection lots (including Lot #GG121624-023) as a Class I recall on October 21, 2025.

Under 21 CFR Part 7, the FDA defines recall classifications as follows:

• Class I Recall: A situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. This is the most urgent recall category.
• Class II Recall: A situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
• Class III Recall: A situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

The FDA's decision to apply a Class I classification to the GenoGenix NAD+ lots was driven by the discovery of elevated levels of bacterial endotoxins within the distributed vials, combined with real-world reports of patient injury.

3. The Broader Sterility-Assurance Recall (July–October 2025)

The Class I action sat on top of a much larger recall. When GenoGenix initiated its voluntary recall on July 30, 2025, it covered roughly 50 categories of sterile injectable — semaglutide, tirzepatide, retatrutide, vitamin and amino-acid blends, and "Lipo MIC + B12" wellness shots among them — all pulled for a lack of sterility assurance. The FDA later assigns a classification (Class I, II, or III) to each recalled product line based on its own risk review, and only the NAD+ endotoxin lot was escalated to the most serious Class I tier. Inspectors documented deficient air filtration, poor cleanroom design, and inadequate validation of sterilization processes, meaning that any vial produced at the facility during the affected window carried a potential risk of bacterial or fungal contamination.

4. The FDA Warning Letter (January 20, 2026)

On January 20, 2026, the FDA issued a formal Warning Letter to GenoGenix, LLC. The warning letter detailed severe violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. Crucially, the FDA noted that GenoGenix was compounding "ineligible" drug substances.

Under Section 503B, outsourcing facilities may only compound bulk drug substances if:

1. The substance appears on the FDA's "503B Bulks List" of substances for which there is a clinical need, OR
2. The drug compounded from the bulk substance is on the FDA's official drug shortage list.

The FDA explicitly stated that NAD+ does not appear on the 503B Bulks List and is not currently on the drug shortage list. As a result, compounding NAD+ in bulk for office use was a direct violation of federal law, rendering the products misbranded and unapproved new drugs. The warning letter also cited bulk compounding of 5-Amino-1MQ, another unapproved research compound popular in wellness clinics, reinforcing that the facility was operating outside the boundaries of federal safety regulations. Following these enforcement actions, GenoGenix ceased all drug compounding and distribution operations.

---

What symptoms indicate an endotoxin reaction after an NAD+ IV drip?

The primary clinical driver of the Class I recall was the contamination of NAD+ vials with bacterial endotoxins. Endotoxins are lipopolysaccharides (LPS) found in the outer membrane of Gram-negative bacteria (such as Escherichia coli, Pseudomonas aeruginosa, and Salmonella). Unlike live bacteria, which can be killed through autoclaving or sterile filtration, endotoxins are highly heat-stable and chemically resistant. Even if a product is completely sterile (free of living microorganisms), it can still contain high levels of endotoxins if the raw materials were contaminated or if bacteria died during the manufacturing process.

When endotoxins enter the systemic circulation via an intravenous infusion, they trigger an immediate, robust activation of the innate immune system. Endotoxins bind to Toll-like receptor 4 (TLR4) on macrophages and monocytes, inducing the rapid release of pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6).

Clinical Manifestations of Endotoxin Contamination

During the investigation of the GenoGenix recall, the FDA documented that at least three patients required emergency room care immediately after receiving NAD+ IV therapy from contaminated lots. The clinical symptoms reported in these cases were typical of an endotoxin-induced pyrogenic response (fever-inducing reaction) and systemic inflammatory response syndrome (SIRS):

• Sudden, Uncontrollable Shaking and Rigors: Patients experienced severe, involuntary shivering within minutes of starting the infusion. This occurs as the hypothalamus, triggered by cytokines, abruptly resets the body's set-point temperature, causing the body to perceive normal room temperature as freezing.
• Acute Hypotension (Low Blood Pressure): The massive release of nitric oxide induced by inflammatory cytokines causes widespread systemic vasodilation. This leads to a sudden drop in blood pressure, presenting as dizziness, confusion, fainting, or shock.
• High Fever and Chills: Body temperature rises rapidly, often exceeding $101^\circ\text{F}$ ($38.3^\circ\text{C}$), accompanied by profuse sweating as the body attempts to shed heat.
• Severe Body Aches and Headache: Cytokine-mediated inflammation in peripheral tissues and the central nervous system causes intense, diffuse muscle aches (myalgia) and severe, throbbing headaches.
• Nausea, Vomiting, and Gastrointestinal Distress: Systemic inflammation and hypotension compromise splanchnic blood flow, leading to acute abdominal cramping and vomiting.

[Endotoxin Contamination in IV Vial]
               │
               ▼
[Intravenous Injection into Bloodstream]
               │
               ▼
[Binding to TLR4 on Immune Cells (Monocytes/Macrophages)]
               │
               ▼
[Rapid Release of Pro-inflammatory Cytokines (TNF-α, IL-1, IL-6)]
        ┌──────┴──────────────────────────────────┐
        ▼                                         ▼
[Hypothalamic Reset]                     [Systemic Vasodilation]
  • High Fever & Chills                    • Acute Hypotension
  • Uncontrollable Shaking/Rigors          • Dizziness and Syncope
  • Diffuse Muscle Aches (Myalgias)        • Risk of Septic Shock

In severe cases, high endotoxin levels can lead to endotoxic shock, disseminated intravascular coagulation (DIC), multi-organ failure, and death. Because med spas and IV bars often lack the advanced monitoring equipment and emergency resuscitation tools found in hospitals, administering compounded injectables contaminated with endotoxins carries a high clinical risk.

---

What is the difference between food-grade and sterile pharmaceutical-grade NAD+?

A critical issue in the compounding of wellness injectables is the quality of the raw bulk drug substances. The FDA compounding directorate issued a specific alert reminding compounders that food-grade bulk ingredients are not suitable for sterile injection preparations.

Raw materials used in compounding must meet strict quality standards to ensure safety:

• Pharmaceutical Grade (API): Active Pharmaceutical Ingredients (APIs) must be manufactured in facilities that comply with CGMP standards. They must undergo rigorous testing to establish identity, purity, potency, and the absence of impurities, heavy metals, solvents, and endotoxins. Pharmaceutical-grade substances are accompanied by a Certificate of Analysis (CoA) verifying that they meet United States Pharmacopeia (USP) or National Formulary (NF) monographs.
• Food Grade: Food-grade ingredients are manufactured under standards suitable for ingestion (the gastrointestinal tract). The human digestive system possesses robust barriers, including highly acidic gastric juices, digestive enzymes, and a mucosal barrier, which prevent the absorption of many microbes and toxins. Consequently, food-grade standards permit much higher thresholds of bioburden (total microbial count) and do not require testing for pyrogens or endotoxins.

When a compounding pharmacy uses cheap, food-grade NAD+ powder intended for oral supplements to prepare an intravenous solution, they bypass the protective barriers of the gastrointestinal tract. Injecting food-grade material directly into a vein introduces unverified impurities, particulate matter, and high levels of bacterial endotoxins directly into the bloodstream, triggering the severe immunological reactions described above.

Regulatory Comparison: 503A vs. 503B Compounding

---

Is oral NAD+ or NMN a safer alternative to IV therapy?

Given the sterility and endotoxin risks of compounded IV preparations, many patients and clinicians are shifting toward oral precursors to support cellular NAD+ levels. The primary oral precursors are Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN).

Nicotinamide Riboside (NR)

Nicotinamide riboside is a trace vitamin found in milk and a structural precursor to NAD+. Once ingested, NR is converted into NMN by nicotinamide riboside kinases (NRK1 and NRK2), and NMN is subsequently converted into NAD+. Human clinical trials have demonstrated that oral NR is highly bioavailable and effectively raises NAD+ levels in blood cells in a dose-dependent manner.

Importantly, NR has been evaluated in multiple randomized, double-blind, placebo-controlled trials. Doses up to 1,000 mg twice daily for up to several months have shown an excellent safety profile, with no reports of flushing, cardiovascular stress, gastrointestinal pain, or hepatotoxicity. In the United States, specific high-purity NR formulations have achieved Generally Recognized as Safe (GRAS) status from the FDA for use in dietary supplements, providing a level of quality assurance that compounded IV infusions lack.

Nicotinamide Mononucleotide (NMN)

Nicotinamide mononucleotide is another direct precursor to NAD+. In 2022, the FDA took the position that NMN could no longer be marketed as a dietary supplement because it had been authorized for investigation as a new drug — a decision grounded in the FD&C Act's drug-exclusion provision, not in any safety concern. In September 2025, however, the FDA reversed that position and concluded that NMN is not excluded from the dietary-supplement definition, clearing a path for it to be sold as a supplement ingredient again. Clinical trials evaluating NMN in humans have shown that oral doses (typically 250 mg to 500 mg daily) are well-tolerated and raise blood NAD+ levels, though large-scale long-term safety studies are still ongoing.

Safety and Efficacy Comparison

Compared to intravenous NAD+ infusions, oral precursors offer several clinical advantages:

1. No Sterility or Endotoxin Risks: Because oral supplements are ingested, they do not carry the risk of systemic septic reactions or endotoxin shock associated with contaminated sterile injectables.
2. No Infusion-Related Adverse Events: Oral supplements do not trigger the acute chest pressure, nausea, vomiting, or rapid heart rate caused by rapid intravenous delivery of intact NAD+.
3. High Tolerability: Patients do not need to spend hours hooked to an IV line under clinical supervision to manage side effects.
4. Lower Cost: IV NAD+ infusions typically cost between $300 and $1,000 per session, whereas a monthly supply of high-quality oral NR or NMN costs between $45 and $90.
5. Steady State Levels: Daily oral supplementation supports more stable, consistent intracellular NAD+ levels over time, whereas IV infusions cause a transient spike in plasma levels followed by rapid clearance and excretion.

While IV therapy is marketed as a premium option, the clinical literature suggests that oral precursors represent a safer, more practical, and more cost-effective method for supporting systemic NAD+ levels.

---

How can you verify if your IV bar sources compounded NAD+ safely?

For patients who choose to pursue NAD+ IV therapy, it is critical to verify the source and safety standards of the injectable medication. The same supply-chain scrutiny that applies to verifying medical injectables against counterfeits applies here: you are buying a compounded product, so the manufacturer matters. You can use this verification checklist to assess the safety practices of an IV bar or wellness clinic:

1. Identify the Compounding Source

• Question to Ask: "Which compounding pharmacy or outsourcing facility manufactured this NAD+ vial?"
• Verification Step: Request the exact name and location of the manufacturer. If the clinic refuses to disclose the source pharmacy, do not proceed with the treatment.

2. Verify 503B Registration (If Sourced in Bulk)

• Question to Ask: "Is the sourcing pharmacy an FDA-registered 503B outsourcing facility?"
• Verification Step: If the clinic purchases bulk vials for "office use" (which is standard for IV bars), the pharmacy must be registered as a 503B facility. Search the official FDA 503B Outsourcing Facilities Registry to confirm their active registration and check for recent FDA inspection reports or Form 483 observations detailing sanitary violations.

3. Check for Recalls and Warning Letters

• Question to Ask: "Has this pharmacy been subject to any FDA warning letters, Class I or II recalls, or state board of pharmacy disciplinary actions within the last 24 months?"
• Verification Step: Search the FDA Enforcement Report database and the FDA Warning Letters portal using the name of the compounding pharmacy. Verify that the pharmacy was not involved in the GenoGenix recalls or similar sterility actions.

4. Confirm Clinical Supervision and Assessment

• Question to Ask: "Will a licensed physician, nurse practitioner, or physician assistant review my medical history and perform an assessment before my first infusion?"
• Verification Step: Safe clinical practice requires a comprehensive medical history review, including assessment of cardiovascular, renal, and hepatic function, prior to administering IV therapies. Avoid clinics that administer IV infusions without a formal medical evaluation or under the supervision of unlicensed staff.

5. Check Emergency Readiness

• Question to Ask: "What protocols are in place if I experience chest pressure, severe nausea, or an acute drop in blood pressure during the infusion? What emergency medications are on site?"
• Verification Step: The clinic should have clear protocols for managing infusion reactions (e.g., immediately stopping the drip, administering IV fluids, or using rescue medications) and must have licensed medical professionals on site who can recognize and manage these complications.

---

FAQ

What are the immediate signs of an infusion reaction during an NAD+ IV drip?

Common infusion reactions include chest tightness, shortness of breath, severe stomach cramping, nausea, headache, and muscle soreness. These symptoms are usually dose-rate dependent; slowing down the infusion rate typically reduces their severity. However, if you experience sudden uncontrollable shivering, high fever, or severe dizziness (signs of potential endotoxin contamination), the infusion must be stopped immediately, and you should seek emergency medical attention.

Why is NAD+ IV therapy so expensive compared to other treatments?

IV NAD+ infusions are priced as premium wellness services, typically ranging from $300 to $1,000 per session. The cost is driven by the clinical monitoring required during the three- to four-hour infusion time, the pricing of compounded sterile vials, and the markup applied by commercial med spas and wellness clinics. The high cost is not a reflection of superior clinical efficacy or FDA approval.

Can a patient with kidney or liver disease receive NAD+ IV therapy?

Patients with renal or hepatic impairment should avoid experimental IV therapies. Compounded injectables put additional metabolic demands on the liver and kidneys, and the risk of impurity exposure is higher. Always consult your primary care physician or specialist before undergoing wellness infusions if you have pre-existing organ dysfunction.

How does the FDA define a Class I recall?

Under federal regulations, a Class I recall is the most urgent classification, applied when there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. This is in contrast to Class II recalls (remote risk or temporary consequences) and Class III recalls (unlikely to cause adverse consequences).

Can oral nicotinamide riboside (NR) cause facial flushing?

Unlike traditional niacin (nicotinic acid), nicotinamide riboside (NR) does not bind to the GPR109A receptors that trigger prostaglandin-mediated vasodilation. Consequently, oral NR does not cause the uncomfortable skin flushing, itching, or redness commonly associated with high-dose niacin supplements.

---

Sources

1. FDA bulk compounding reminding guidance: U.S. Food and Drug Administration. (2025). FDA Reminds State Boards of Pharmacy and Compounders About Certain Bulk Drug Substances. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-state-boards-pharmacy-and-compounders-about-certain-bulk-drug-substances
2. FDA recall database entry: U.S. Food and Drug Administration. (2025). GenoGenix, LLC Voluntary Drug Recalls & Class I Classifications. https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls
3. Compounded NAD+ clinical trial review: Radenkovic, D., & Verdin, E. (2020). Clinical Evidence for NAD+ Precursors and Intravenous Infusions: A Systematic Review of Human Trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC10104843/
4. FDA Warning Letter: U.S. Food and Drug Administration. (2026). Warning Letter: GenoGenix, LLC (#718739, dated January 20, 2026). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026
5. NIH B12 and NAD+ Fact Sheets: National Institutes of Health, Office of Dietary Supplements. Nutrient Reference Guides and Longevity Precursors. https://ods.od.nih.gov/